FOLH1 and prostate carcinoma: Prostate-specific membrane antigen (PSMA) positron emission tomography (PET) is a well-established technique for the assessment of prostate cancer (PCa) biochemical recurrence (BCR) [1] with a significant impact on patient management due to high sensitivity and specificity [2].